Search research articles
Contact Us
Filters
Showing results (301-310 of 336) with videos related to
Page
of 34
Sort By:
JNCI Cancer Spectrum
|
December 14, 2024
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)
Florence Joly, Fernando Bazan, Delphine Garbay, et al.
BMC Cancer
|
June 7, 2024
The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers
Lucie Thorel, Jordane Divoux, Justine Lequesne, et al.
Urologic Oncology
|
June 20, 2015
Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features
Romain Mathieu, Géraldine Pignot, Alexandre Ingles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Philipp Harter, Frederik Marmé, Andrés Redondo, et al.
Gynecologic Oncology
|
July 28, 2022
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
Florence Joly, Michel Fabbro, Dominique Berton, et al.
The Lancet. Oncology
|
February 4, 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
Sandro Pignata, Domenica Lorusso, Florence Joly, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 19, 2025
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial
Guillaume Beinse, Karen Leroy, Pierre-Alexandre Just, et al.
The Lancet. Oncology
|
December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial
Cora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
Cancers
|
March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
Jean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 18, 2025
European training requirements for gynecological oncology: the European Society of Gynaecological Oncology Curriculum
Blanca Gil-Ibañez, René H M Verheijen, Basel Refky, et al.
Page
of 34
Search research articles
Search
Showing results (301-310 of 336) with videos related to
Sort By:
Page
of 34
JNCI Cancer Spectrum
|
December 14, 2024
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)
Florence Joly, Fernando Bazan, Delphine Garbay, et al.
BMC Cancer
|
June 7, 2024
The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers
Lucie Thorel, Jordane Divoux, Justine Lequesne, et al.
Urologic Oncology
|
June 20, 2015
Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features
Romain Mathieu, Géraldine Pignot, Alexandre Ingles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Philipp Harter, Frederik Marmé, Andrés Redondo, et al.
Gynecologic Oncology
|
July 28, 2022
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
Florence Joly, Michel Fabbro, Dominique Berton, et al.
The Lancet. Oncology
|
February 4, 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
Sandro Pignata, Domenica Lorusso, Florence Joly, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 19, 2025
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial
Guillaume Beinse, Karen Leroy, Pierre-Alexandre Just, et al.
The Lancet. Oncology
|
December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial
Cora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
Cancers
|
March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
Jean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 18, 2025
European training requirements for gynecological oncology: the European Society of Gynaecological Oncology Curriculum
Blanca Gil-Ibañez, René H M Verheijen, Basel Refky, et al.
Page
of 34